SCHEMBL618332

SCHEMBL618332

O=C1CC=Nc2ncccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 3/20 0.41
NSD2 O96028 3/20 0.41
PAX8 Q06710 3/20 0.41
KMT2A Q03164 2/20 0.41
ABL1 P00519 1/20 0.41
PLCG1 P19174 1/20 0.41
CES1 P23141 1/20 0.41
RIN1 Q13671 1/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41
S100A4 P26447 5/20 0.37
CDC25B P30305 3/20 0.37
PTPRC P08575 2/20 0.37
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37
PTPN13 Q12923 1/20 0.37
PADI1 Q9ULC6 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498808 1.00 TDP2 (0.41) TDP2NSD2PAX8KMT2AABL1
Hydrochloric Acid SCHEMBL15327096 0.98 TDP2 (0.39) TDP2NSD2PAX8KMT2AABL1
SCHEMBL29088936 0.77 TDP1 (0.32) TDP2NSD2PAX8KMT2AABL1
SCHEMBL26512083 0.74 TDP2 (0.38) TDP2NSD2PAX8KMT2AABL1
SCHEMBL30777010 0.73 PLK4 (0.35)
SCHEMBL1815830 0.73 GSK3B (0.38) KMT2AABL1PLCG1MEN1CYP1A2
SCHEMBL331804 0.72 TDP2 (0.43) TDP2NSD2PAX8KMT2AABL1
SCHEMBL255497 0.71
SCHEMBL31434916 0.69 ALDH1A1 (0.33) ALDH1A1
SCHEMBL28077985 0.69 S100A4 (0.45) TDP2NSD2PAX8KMT2AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336629-A1 Tricyclic Derivatives Useful As PARP7 Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-10-10 US claimed
US-11746112-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) 2023-09-05 US claimed
EP-3781263-A2 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS Printnet Kereskedelmi és Szolgátató Kft. (HU) 2021-02-24 EP claimed
EP-3312177-A2 TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Jeil Pharmaceutical Co., Ltd. (KR) 2018-04-25 EP claimed
CN-102245612-B Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same JE IL PHARMACEUTICAL CO LTD 2014-11-05 CN claimed
EP-2709996-A1 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS SANOFI (FR) 2014-03-26 EP claimed
WO-2012159959-A1 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS SANOFI (FR) 2012-11-29 WO claimed
EP-0447484-A1 ANTIBACTERIAL QUINOLONE COMPOUNDS THE UPJOHN COMPANY (US) 1991-09-25 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP claimed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO claimed
EP-0127135-A2 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones SCHERING CORPORATION (US) 1984-12-05 EP claimed
JP-64003181-A None JP disclosed
US-12503439-B2 Heteroaryl compounds for the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
EP-4582423-A1 NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF Hanmi Pharm. Co., Ltd. (KR) 2025-07-09 EP disclosed
CN-120136886-A PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof 中山大学 2025-06-13 CN disclosed
EP-0132845-B1 NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF Dainippon Pharmaceutical Co., Ltd. (JP) 1988-04-13 EP disclosed
US-4621088-A N-acyl derivatives of amino acids and their esters, and drugs in which they are present PANMEDICA (FR) 1986-11-04 US disclosed
EP-0031561-B1 A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT MERCK & CO. INC. (US) 1985-04-10 EP disclosed
EP-0027752-B1 NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Société anonyme dite: LABORATOIRE ROGER BELLON (FR) 1983-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503439-B2 Heteroaryl compounds for the treatment of pain TRPV1, SCN3A, KCNN3 TDP2 2588/4885NSD2 2783/4885PAX8 3822/4885
US-11746112-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms MYH2, MYLK2, MYO1B TDP2 205/4885NSD2 3333/4885PAX8 3249/4885
US-20240336629-A1 Tricyclic Derivatives Useful As PARP7 Inhibitors PARP1, PARP2, PARP11 TDP2 144/4885NSD2 638/4885PAX8 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.